Author: jessica

Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair

by on September 9, 2025

Menlo Park, Calif., September 9, 2025 – Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair. “David’s…

Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data

by on May 14, 2025

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP Menlo Park, Calif., May 14, 2025 – Nuvig Therapeutics, Inc.,…

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

by on December 5, 2024

Menlo Park, Calif., December 5, 2024 – Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced today the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture…